Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Nuclear medicine in the assessment of differentiated thyroid cancer CLINICAL RADIOLOGY Rutherford, G., Franc, B., O'Connor, A. 2008; 63 (4): 453–63

Abstract

Despite modern multi-modality treatment, 10-30% of patients treated for differentiated thyroid cancer (DTC) ultimately develop local recurrence or metastatic disease. These malignancies are frequently slow-growing and secondary surgical resection is often undertaken along with radioactive iodine treatment. Correlation of radiological imaging with nuclear medicine studies is essential for individualized treatment planning, and to optimize this management. Radiologists should be familiar with the interpretation of various nuclear medicine studies used to image differentiated thyroid neoplasms.

View details for DOI 10.1016/j.crad.2007.08.002

View details for Web of Science ID 000254516900015

View details for PubMedID 18325367